for a listing of the adverse events leading to discontinuations in each treatment arm.
† Patients completed original 96-week protocol but did not continue into extension. ‡ Including 13 raltegravir and 5 efavirenz recipients who relocated or from terminated study sites.
N (%) = number (percent) of patients in each sub-category. 
Cardiac Disorders
Number (%) of Patients With Specific Clinical Adverse Experiences (Incidence >0% in One or More Treatment Groups) by System Organ Class -All Events -Moderate or SevereDouble-Blind Phase, All Available Data
Number ( Number (%) Figure S2 for comparison of lipid values to NCEP goals. † Within-group 95% confidence intervals (CI) were based on t-distribution. ‡ The 95% confidence intervals (CI) and p-values for treatment difference were calculated from an ANOCOVA model with terms for baseline lipid level and treatment. N = Number of patients in the treatment group. The Last-Observation-Carried-Forward approach was applied for missing data because of increased lipids (such as the addition lipid-lowering medications). Figure S1 . Time to first-reported adverse neuropsychiatric experience.
Hepatobiliary Disorders
Time to neuropsychiatric symptoms was defined as the time between randomization and the onset of first nervous system adverse experience in the expanded list (2). A patient with a single neuropsychiatric symptom and a patient with several neuropsychiatric side-effects of diverse types were each tallied once in the composite frequency analysis of patients with neuropsychiatric adverse experiences on the basis of the first reported event. The time to the first reported neuropsychiatric event was significantly longer for raltegravir than efavirenz recipients (log-rank p <0.001).
37 Figure S2 . Lipid values at baseline and at Week 240 by treatment group contrasted with NCEP targets.
